Osteoporosis |
|
 |
|
Osteoporosis is a disease which affects mostly women. Osteoporosis is a loss of bone tissue, resulting in bones that are brittle and liable to fractures. Infection, injury and synovitis can cause localized osteoporosis of adjacent bone. It can also result from prolonged steroid therapy. Depending on the extent of demineralization of the bone, it may be accompanied by pain, particularly of the lower back. The condition can be prevented in the menopause by administration of estrogen hormones, as well as other agents. Products: Bone resorption inhibitor
Evista
Estrogen is a hormone which among other actions, regulates the turnover (formation and destruction) of bone. Decreases in estrogen levels that are seen after menopause or after removal of the ovaries, lead to a loss of bone density and weakened bones, a condition called osteoporosis. Raloxifene decreases bone turnover and increases bone density although not to the same extent as estrogen itself. This makes bones stronger and prevents fractures in women with osteoporosis. Raloxifene is called a "selective estrogen receptor modulator" since it has effects like estrogen on some tissues but inhibits the effects of estrogen on other tissues.
Fosamax
Fosamax (generic name: alendronate) is prescribed for the prevention and treatment of osteoporosis, the brittle bone disease, in postmenopausal women. It is also used to increase bone mass in men with osteoporosis, and is prescribed for both men and women who have developed a form of osteoporosis sometimes caused by steroid medications such as prednisone. This drug can also be used to relieve Paget's disease of bone, a painful condition that weakens and deforms the bones.
|
|
Osteoporosis
|
|
My Basket